CGS-20625
 | |
| Systematic (IUPAC) name | |
|---|---|
| 5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)-cyclohepta[b]pyrazolo[3,4-d]pyridin-3(2H)-one | |
| Clinical data | |
| oral | |
| Pharmacokinetic data | |
| Bioavailability | 41% |
| Identifiers | |
111205-55-1  | |
| None | |
| PubChem | CID 163844 |
| ChemSpider |
143700  |
| Chemical data | |
| Formula | C18H19N3O2 |
| 309.36236 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
CGS-20625 is an anxiolytic drug used in scientific research. It has similar effects to, and binds to the same target as benzodiazepine drugs,[1] but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.[2][3]
CGS-20625 produces anxiolytic and anticonvulsant effects, but with no sedative effects even at high doses, and no significant muscle relaxant effects.[4] It is orally active in humans, but with relatively low bioavailability.[5]
References
- ↑ Khom S, Baburin I, Timin EN, Hohaus A, Sieghart W, Hering S (Feb 2006). "Pharmacological properties of GABAA receptors containing gamma1 subunits". Mol Pharmacol. 69 (2): 640–9. doi:10.1124/mol.105.017236. PMID 16272224.
- ↑ Bennett DA (1987). "Pharmacology of the pyrazolo-type compounds: agonist, antagonist and inverse agonist actions". Physiol. Behav. 41 (3): 241–5. doi:10.1016/0031-9384(87)90360-X. PMID 2893398.
- ↑ Brunner LA, Luders RC (Aug 1991). "Determination of a potential anxiolytic drug (CGS 20625) in human plasma by high-performance liquid chromatography". J Chromatogr. 568 (2): 487–93. doi:10.1016/0378-4347(91)80188-I. PMID 1686029.
- ↑ Williams M, Bennett DA, Loo PS et al. (Jan 1989). "CGS 20625, a novel pyrazolopyridine anxiolytic". J Pharmacol Exp Ther. 248 (1): 89–96. PMID 2563294.
- ↑ Hirschberg Y, Oberle RL, Ortiz M, Lau H, Markowska M (Feb 1995). "Oral absorption of CGS-20625, an insoluble drug, in dogs and man". J Pharmacokinet Biopharm 23 (1): 11–23. doi:10.1007/BF02353783. PMID 8576841.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||